Correlation Between Aerovate Therapeutics and INmune Bio

Can any of the company-specific risk be diversified away by investing in both Aerovate Therapeutics and INmune Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aerovate Therapeutics and INmune Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Aerovate Therapeutics and INmune Bio, you can compare the effects of market volatilities on Aerovate Therapeutics and INmune Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aerovate Therapeutics with a short position of INmune Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aerovate Therapeutics and INmune Bio.

Diversification Opportunities for Aerovate Therapeutics and INmune Bio

-0.16

Correlation Coefficient

Aerovate Therapeutics  INmune Bio

Good diversification

The 3 months correlation between Aerovate and INmune is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Aerovate Therapeutics and INmune Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on INmune Bio and Aerovate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aerovate Therapeutics are associated (or correlated) with INmune Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of INmune Bio has no effect on the direction of Aerovate Therapeutics i.e., Aerovate Therapeutics and INmune Bio go up and down completely randomly.

Pair Corralation between Aerovate Therapeutics and INmune Bio

Given the investment horizon of 90 days Aerovate Therapeutics is expected to generate 0.83 times more return on investment than INmune Bio. However, Aerovate Therapeutics is 1.2 times less risky than INmune Bio. It trades about 0.17 of its potential returns per unit of risk. INmune Bio is currently generating about -0.05 per unit of risk. If you would invest  186.00  in Aerovate Therapeutics on September 1, 2024 and sell it today you would earn a total of  77.00  from holding Aerovate Therapeutics or generate 41.4% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Aerovate Therapeutics  vs.  INmune Bio

Aerovate Therapeutics

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Aerovate Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Aerovate Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

INmune Bio

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days INmune Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Aerovate Therapeutics and INmune Bio

The main advantage of trading using opposite Aerovate Therapeutics and INmune Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aerovate Therapeutics position performs unexpectedly, INmune Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in INmune Bio will offset losses from the drop in INmune Bio's long position.

The idea behind Aerovate Therapeutics and INmune Bio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.